Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937699 | 0.89 | ABL1 (0.37) | NPC1RAB9AADORA2AADORA1DHODH | |
| SCHEMBL1936059 | 0.79 | PRMT5 (0.41) | CYP11B1CYP11B2CYP1A2DHODH | |
| SCHEMBL1938105 | 0.78 | PTGS1 (0.36) | NPC1RAB9AADORA2AADORA1TEK | |
| SCHEMBL1937496 | 0.77 | ABL1 (0.38) | NPC1RAB9ACYP3A4CYP1A2CYP2C9 | |
| SCHEMBL1937723 | 0.77 | ABL1 (0.38) | NPC1RAB9AADORA2AADORA1DHODH | |
| SCHEMBL1936286 | 0.76 | ALDH1A1 (0.34) | NPC1RAB9AADORA2AADORA1DHODH | |
| SCHEMBL3581885 | 0.72 | NPC1 (0.44) | CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL1937991 | 0.71 | ABL1 (0.39) | NPC1RAB9AADORA2AADORA1DHODH | |
| SCHEMBL1937549 | 0.69 | NPC1 (0.36) | NPC1RAB9AADORA2AADORA1 | |
| SCHEMBL15886391 | 0.69 | PDE2A (0.41) | NPC1RAB9AADORA2ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2330891-A1 | FUNGICIDAL PYRIDAZINES | E. I. du Pont de Nemours and Company (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110136762-A1 | FUNGICIDAL PYRIDAZINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2010036553-A1 | FUNGICIDAL PYRIDAZINES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136762-A1 | FUNGICIDAL PYRIDAZINES | PRDX1, PNPO, PRXL2A | CYP11B1 132/4885CYP11B2 202/4885CYP17A1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.